Medical oncologist Renier Brentjens describes an innovative therapy to modify T cells to recognize the CD19 protein.
Medical oncologist Alexander Lesokhin discusses a phase I dose escalation of an anti-PD-1 immunotherapy in patients with hematologic cancers.
Hematologist-oncologist Ellin Berman discusses a randomized phase III clinical trial of an investigational oral drug, sapacitabine, for AML in elderly patients.
Mutational profiling can improve risk stratification and inform prognostic and therapeutic decisions regarding patients with AML.
Leader of the Acute Lymphoblastic Leukemia Program Dan Douer discusses a study examining late relapses among APL patients.
Medical oncologist Omar Abdel-Wahab discusses studies that assessed the functional implications of ASXL1 mutations in the hematopoietic compartment.
Medical oncologist Omar Abdel-Wahab discusses data linking TET2 with the function of cytosine deaminases as a pathway toward DNA demethylation.
Medical oncologist Omar Abdel-Wahab discusses a study that validates a lower-risk prognostic scoring system’s ability to identify higher-risk MDS patients.
Martin Tallman, a hematologist-oncologist at Memorial Sloan Kettering, discusses a clinical trial combining arsenic trioxide with all-tansretinoic acid (ATRA) for the treatment of patients with APL.
Animated video shows how Memorial Sloan Kettering researchers are using genetically engineered T-cells to recognize and attack cancer.
MSKCC scientists are engineering immune-system cells called T cells so that they can identify and destroy leukemia and prostate cancer cells.
We provide a collaborative team approach to the management of approximately 350 new patients with leukemia annually. A primary doctor closely coordinates the care of hematologists, medical and radiation oncologists, bone marrow and stem cell specialists, pathologists, and others. The team meets weekly to discuss and update each patient’s treatment plan. Our many clinical trials incorporate innovative therapies for various types of leukemias. We are recognized as leaders in immunotherapy and the development of novel drug strategies for a number of leukemias.